Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology, Inc. director Steven M. Chaouki received a grant of stock options for 27,907 shares of common stock on March 31, 2026. The options carry an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.
MAIA Biotechnology director Ramiro Guerrero received a grant of stock options as equity compensation. He was awarded 27,258 stock options on March 31, 2026 with an exercise price of $1.40 per share, each option representing one share of common stock.
The options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan, vest 100% on the grant date, and are exercisable beginning March 31, 2026. Following this grant, Guerrero holds 27,258 stock options directly, with the options scheduled to expire on March 31, 2036.
MAIA Biotechnology, Inc. director Louie Ngar Yee received a grant of stock options for 33,748 shares of common stock. The options were granted on March 31, 2026 at an exercise price of $1.40 per share, vest 100% on the grant date, and are immediately exercisable.
Following this grant, he holds 33,748 stock options directly, which are scheduled to expire on March 31, 2036.
MAIA Biotechnology, Inc. director Cristian Luput received a grant of stock options representing the right to acquire 28,556 shares of common stock. The options were granted on March 31, 2026, with an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable beginning that day until March 31, 2036. This is a compensation-related award rather than an open-market purchase or sale, and leaves Luput holding 28,556 stock options directly following the transaction.
MAIA Biotechnology, Inc. director Theagene Jean-Manasse received a grant of stock options covering 27,258 shares of common stock. The options have an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.
MAIA Biotechnology director Stan Smith reported an award of stock options as compensation. On March 31, 2026, an entity associated with him, The Stan V. Smith Trust Dated 1993, received 33,099 stock options under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
The options give the right to buy an equal number of shares of common stock at an exercise price of $1.40 per share. They vest 100% on the grant date and are exercisable beginning that day, expiring on March 31, 2036. After this grant, the filing shows 33,099 options indirectly beneficially owned.
MAIA Biotechnology, Inc. disclosed that its Board approved one-time cash bonuses for two senior executives following the company’s recent capital raise. On March 27, 2026, the Board granted a $312,610 bonus to Chief Executive Officer Vlad Vitoc and a $50,000 bonus to Head of Finance Jeffrey Himmelreich, paid on March 31, 2026.
The company also included customary cautionary language regarding forward-looking statements, outlining risks related to clinical studies, regulatory approvals, manufacturing, market acceptance, and intellectual property protection.
MAIA Biotechnology reported encouraging survival data from its ongoing Phase 2 THIO-101 trial in non-small cell lung cancer. Eight patients treated with ateganosine followed by cemiplimab have overall survival beyond two years, without receiving additional lines of therapy.
The poster highlighted one third-line patient with 33 months survival compared with published 5.8-month expectations for similar heavily pre-treated patients, and four second-line patients with survival over 30 months versus documented 10.5-month overall survival for standard second-line care. THIO-101 Parts A and B treated 79 patients, and the Part C expansion is enrolling up to 48 participants in Asia and Europe.
MAIA describes ateganosine as a first-in-class telomere-targeting agent designed to induce selective cancer cell death and stimulate both innate and adaptive immune responses when sequenced with PD-(L)1 inhibitors. The company states that ateganosine followed by cemiplimab has shown an acceptable safety profile to date in this heavily pre-treated population.
MAIA Biotechnology, Inc. furnished an update under Regulation FD by filing a scientific poster as an exhibit. The poster, titled “Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation in Abstract NSCLC Relapsed-Patients Treated with Ateganosine and ICI in the THIO-101 Trial,” is being presented at the European Lung Cancer Congress 2026 in Copenhagen and posted on the company’s website on March 27, 2026. It discusses data from relapsed non-small cell lung cancer patients in the THIO-101 trial and is filed as Exhibit 99.1. The company notes that the poster includes forward-looking statements and cautions that investors should not place undue reliance on them.
MAIA Biotechnology files its annual report describing rapid progress for its lead cancer drug, ateganosine (THIO), and a growing telomere-targeting pipeline. The company is running the pivotal Phase 2 THIO-101 trial in third-line non-small cell lung cancer (NSCLC) and has initiated the Phase 3 THIO-104 trial comparing ateganosine plus a checkpoint inhibitor to chemotherapy in up to 300 patients.
Ateganosine has shown encouraging interim results in NSCLC, including median overall survival around 17.8 months in heavily pretreated third-line patients, strong disease control and overall response rates, and generally manageable safety. MAIA has secured multiple FDA designations, including Orphan Drug, Fast Track and rare pediatric disease status, and expanded global collaborations with Regeneron, BeiGene/BeOne and Roche, while building a second-generation telomere-targeting prodrug platform and an extensive patent estate.